MX382095B - Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. - Google Patents

Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.

Info

Publication number
MX382095B
MX382095B MX2018013349A MX2018013349A MX382095B MX 382095 B MX382095 B MX 382095B MX 2018013349 A MX2018013349 A MX 2018013349A MX 2018013349 A MX2018013349 A MX 2018013349A MX 382095 B MX382095 B MX 382095B
Authority
MX
Mexico
Prior art keywords
benzoimidazol
diethylamino
acrylamide
hydroxy
butyl
Prior art date
Application number
MX2018013349A
Other languages
English (en)
Other versions
MX2018013349A (es
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MX2018013349A publication Critical patent/MX2018013349A/es
Publication of MX382095B publication Critical patent/MX382095B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen Polimorfos de Formas cristalinas del 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida. También se presentan composiciones farmacéuticas y los usos de las mismas, Formas compuestas y composiciones, para el tratamiento de enfermedades y afecciones.
MX2018013349A 2016-05-02 2017-05-01 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. MX382095B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (2)

Publication Number Publication Date
MX2018013349A MX2018013349A (es) 2019-02-20
MX382095B true MX382095B (es) 2025-03-13

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013349A MX382095B (es) 2016-05-02 2017-05-01 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.

Country Status (20)

Country Link
US (2) US10626092B2 (es)
EP (2) EP3939966A1 (es)
JP (1) JP2019514905A (es)
KR (1) KR20190005904A (es)
CN (1) CN109414425A (es)
AR (1) AR108257A1 (es)
AU (1) AU2017261218A1 (es)
BR (1) BR112018072439A2 (es)
CA (1) CA3022011A1 (es)
CL (1) CL2018003109A1 (es)
CO (1) CO2018012941A2 (es)
EA (1) EA201892341A1 (es)
ES (1) ES2886495T3 (es)
IL (1) IL262578A (es)
MA (1) MA44880A (es)
MX (1) MX382095B (es)
PH (1) PH12018502296B1 (es)
SG (1) SG11201809471UA (es)
TW (1) TW201741286A (es)
WO (1) WO2017192451A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157741A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
EP3728205A1 (en) 2017-12-19 2020-10-28 Assia Chemical Industries Ltd Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
US20230159468A1 (en) * 2020-04-22 2023-05-25 Macfarlan Smith Limited Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
AU668181B2 (en) 1992-05-20 1996-04-26 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
CA2376957A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
HK1047895A1 (zh) 1999-07-16 2003-03-14 沃尼尔‧朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US20040091951A1 (en) 2002-02-07 2004-05-13 Axys Pharmaceuticals, Inc. Assay for measuring acetylation or deacetylation activity of an enzyme
PA8569201A1 (es) 2002-03-13 2004-05-21 Array Biopharma Inc "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
WO2003087089A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR046411A1 (es) 2003-09-22 2005-12-07 S Bio Pte Ltd Derivados de bencimidazol. aplicaciones farmaceuticas
US20050159470A1 (en) 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
PT1937650E (pt) 2005-09-08 2011-09-21 S Bio Pte Ltd Compostos heterocíclicos
CA2540459C (en) * 2005-09-08 2014-02-18 S*Bio Pte Ltd Benzimidazole compounds and uses in treating proliferative disorders
EP3449923A1 (en) * 2007-03-07 2019-03-06 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
US20150258068A1 (en) 2012-10-30 2015-09-17 Mei Pharma, Inc. Combination therapies

Also Published As

Publication number Publication date
PH12018502296A1 (en) 2019-07-08
US20200317621A1 (en) 2020-10-08
CN109414425A (zh) 2019-03-01
CL2018003109A1 (es) 2019-04-26
EP3452035A1 (en) 2019-03-13
AR108257A1 (es) 2018-08-01
EP3939966A1 (en) 2022-01-19
SG11201809471UA (en) 2018-11-29
EP3452035A4 (en) 2019-09-25
CA3022011A1 (en) 2017-11-09
US20190152923A1 (en) 2019-05-23
TW201741286A (zh) 2017-12-01
EA201892341A1 (ru) 2019-05-31
EP3452035B1 (en) 2021-07-07
IL262578A (en) 2018-12-31
AU2017261218A1 (en) 2018-11-29
JP2019514905A (ja) 2019-06-06
KR20190005904A (ko) 2019-01-16
MA44880A (fr) 2021-03-17
ES2886495T3 (es) 2021-12-20
BR112018072439A2 (pt) 2019-02-19
WO2017192451A1 (en) 2017-11-09
CO2018012941A2 (es) 2018-12-28
PH12018502296B1 (en) 2022-04-06
MX2018013349A (es) 2019-02-20
US10626092B2 (en) 2020-04-21

Similar Documents

Publication Publication Date Title
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
MX2018003284A (es) Compuestos antifungicos y procesos para hacerlos.
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
PH12017500920B1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
PH12018502296B1 (en) Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof
TWI799397B (zh) 用於治療高血壓之組合物
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
PH12016501613B1 (en) Pyrazines modulators of gpr6
IL259297A (en) Heterocyclic compounds for the treatment of disease
HUE067197T2 (hu) Készítmények patogének által okozott fertõzések kezelésére
MY188420A (en) Crystalline forms of (s)-afoxolaner
WO2015001541A3 (en) Pharmaceutical film composition
HUE065955T2 (hu) Készítmények vulvodynia kezelésére
EP3655379A4 (en) Methods for preparing bis-tetrahydroisoquinoline-containing compounds
GB201500867D0 (en) Compound or mixture of compounds for the treatment of neurodegenerative diseases or oxidative stress injuries
NZ735249A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease
WO2015170340A3 (en) Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
HK40070316B (zh) 用於治疗疾病的杂环化合物
SMT202400184T1 (it) Composizioni per il trattamento di infezioni patogene
HK40015207A (en) Compositions for the treatment of hypertension